Lanreotide CAS:108736-35-2

Lanreotide is primarily used to treat neuroendocrine tumors and other diseases caused by excessive hormone production. Its application includes but is not limited to the following aspects: Neuroendocrine tumor treatment: Lanreotide is widely used to control hormone secretion in insulinomas, pituitary tumors, and gastrointestinal neuroendocrine tumors. By inhibiting the excessive release of growth hormone and other hormones, it helps slow tumor growth and reduce symptoms. Symptom management: For those whose neuroendocrine tumors are inoperable or metastatic, Lanreotide can significantly reduce symptoms such as diarrhea, flushing, and increased stomach acid, thereby improving quality of life. Management of insulin-dependent diseases: In patients with insulinoma, Lanreotide can control blood sugar levels by inhibiting insulin overproduction, reducing the risk of hypoglycemia episodes, and improving patients' quality of life. Clinical Studies and applications: Lanreotide's research is also exploring its potential role in the treatment of other types of cancer and hormone-dependent diseases, including areas such as diabetes-related hormone disorders, obesity and other endocrine abnormalities. Overall, Lanreotide, as an important somatostatin drug, plays a key role in the treatment of neuroendocrine tumors. By regulating hormone levels and reducing symptoms, it offers patients an important treatment option, especially for those requiring long-term management and control, with significant clinical implications.